Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

Trial Details

NCT ID

NCT06238921

Phase

PHASE1 / PHASE2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Stereotactic Radiation
Zimberelimab
Sacituzumab govitecan

Locations (sample)

Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

Provision of signed and dated Informed Consent Form (ICF).
Stated willingness to comply with all study procedures and availability for the duration of the study.
Triple negative breast cancer; to fulfill the requirement of triple negative disease, a breast cancer must express (≤ 10%), by immunohistochemistry…
Breast cancer as documented by extracranial tumor biopsy with brain metastases documented from MRI brain imaging or intracranial surgical pathology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →